Amylin Dissidents Win More Support
Luke Timmerman5/18/09
Two more firms that advise shareholders on proxy voting—Glass, Lewis & Co. and Proxy Governance—have recommended shareholders of Amylin Pharmaceuticals (NASDAQ: AMLN) throw their support behind dissident directors nominated by Eastbourne Capital and billionaire investor Carl Icahn. Glass Lewis is recommending shareholders vote for three of the five dissidents nominated to the 12-member board, while Proxy Governance is recommending all five dissidents. On Friday, another leading proxy adviser, RiskMetrics Group, recommended dissidents win three seats on the board.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
